Adjuvant celecoxib not associated with improved disease-free survival in patients with ERBB2-negative breast cancer
1. The study found no evidence of benefit to disease-free survival when 400 mg of celecoxib was administered once daily for 2 years in...
Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer.
2. Grade 3 or greater adverse events...
Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced...
1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such as sunitinib, was associated...
Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis
1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis.
2. The daratumumab group presented...
Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy...
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone.
2. Severe adverse events occurred more frequently...
BNT162b2 SARS-CoV-2 vaccine is safe but less effective in cancer patients currently receiving treatment
1. After receiving the BNT162b2 SARS-CoV-2 vaccine, fewer cancer patients demonstrated seropositivity for COVID antibodies compared to age-matched healthy controls, but those that were...
Tamoxifen decreases recurrence rates at 25 years in lymph node-negative estrogen-receptor-positive and Erb-B2 Receptor...
1. Tamoxifen reduced the long-term risk of breast cancer metastasis or recurrence and improved survival, especially in large, low-grade progesterone receptor-positive, or Ki-67-positive patients,...
Guideline-concordant multimodal therapy associated with improved mortality outcomes in patients with high-risk prostate cancer
1. Among patients with high-risk prostate cancer receiving guideline-concordant multimodal therapy, prostate cancer-specific mortality outcomes were equivalent among radical prostatectomy, external beam radiotherapy alone,...
Neoadjuvant pembrolizumab with chemoradiotherapy not supported for locally advanced rectal cancer after chemotherapy treatment
1. Although combining pembrolizumab to chemoradiotherapy as part of total neoadjuvant therapy after FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) treatment was safe overall, the difference...
Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone.
2. Improved median progression-free survival and estimated survival...
